Recordati SpA provided earnings guidance for 2014. For the period, revenues are expected to be more than EUR 1 billion, growing by around 8%, due mainly to the consolidation of Opalia Pharma and Laboratorios Casen Fleet acquired in 2013. The operating margin is expected to increase due mainly to an improvement in gross margin as a result of the high margin associated with the newly acquired products and the low margin generated by the terminated products.

Operating income is expected to be more than EUR 220 million, with a margin on sales of 22%, and net income to be more than EUR 150 million with a margin on sales of 15%.